Pure Biologics

Pure Biologics Debt / Assets

The Debt-to-Assets Ratio of Pure Biologics (PUR.WA) as of Nov 12, 2026 is 3.24. In the previous year, Debt-to-Assets Ratio was 6.00 — a change of -46.00% (lower).

Debt / Assets

3.24

YoY

-46.00%

Last updated:

Debt-to-Assets Ratio of Pure Biologics is 2025 3.24 . Debt-to-Assets Ratio of Pure Biologics was 2024 6.00 . It decreases by -46.00% lower compared to the previous year.

The Pure Biologics Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2018
0.01 PLN
Jan 1, 2019
0.25 PLN
Jan 1, 2020
0.26 PLN
Jan 1, 2021
0.07 PLN
Jan 1, 2022
0.09 PLN
Jan 1, 2023
0.57 PLN
Jan 1, 2024
6.00 PLN
Jan 1, 2025
3.24 PLN
The Pure Biologics Debt / Assets history
YEARDebt / AssetsYoY
3.24-46.00%
6.00+954.55%
0.57+556.49%
0.09+31.39%
0.07-75.03%
0.26+7.13%
0.25+1,629.04%
0.01-87.79%
0.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

Debt-to-Assets Ratio of Pure Biologics is 3.24 in 2025.

Debt-to-Assets Ratio of Pure Biologics changed from 6.00 to 3.24, representing a -46.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Pure Biologics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Pure Biologics

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Pure Biologics